Skip to main content

Table 2 Risk factors of everolimus-associated AKI in the RCC group: Cox proportional hazard models

From: Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

Variable

Univariate analysis

Multivariate analysis*

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (per 10 years)

1.83 (1.05–3.21)

0.034

1.54 (0.84–2.81)

0.162

Male (vs female)

0.85 (0.19–3.82)

0.836

  

DM

0.70 (0.16–3.14)

0.643

  

HTN

0.74 (0.23–2.36)

0.609

  

eGFR (per 10 mL/min/1.73 m2)

0.74 (0.57–0.96)

0.022

0.70 (0.49–1.00)

0.047

Radical nephrectomy

0.64 (0.20–2.06)

0.456

  

Proteinuria

2.23 (0.75–6.63)

0.150

  

ACE inhibitor/ARB

1.21 (0.34–4.34)

0.769

  

Diuretics

1.09 (0.38–3.13)

0.880

  
  1. AKI, acute kidney injury; RCC, renal cell carcinoma; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
  2. *This model includes age, sex, and eGFR.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us